Wild-typeKRAS(KRASWT) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role ofKRASWToverexpression in lung cancer progression is largely unexplored. Here, we identify and characterize a KRAS-responsive lncR...
FBXL6 is highly expressed in HCC as well as other human cancers (P < 0.001). Interestingly, FBXL6 drives HCC in transgenic mice. Mechanistically, elevated FBXL6 promotes the polyubiquitination of both wild-type KRAS and KRASG12Dat lysine 128, leading to the activation of both KRAS and ...
KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies - ScienceDirectA. GeorgiouA. StewartP. ThavasuE.A. CokerS. PoelsterlB. Al-Lazikani...
with NTRK fusions confined to those tumors that are pan-wild type KRAS, NRAS, and BRAF. In one study of 8 colorectal cancers harboring NTRK fusions, 7 were found in the small subset that were dMMR (MLH-1)/M...
Connecting cancer biology and clinical outcomes to imaging in KRAS mutant and wild-type colorectal cancer liver tumors following selective internal radiation therapy with yttrium-90. Abdominal Radiology. 2016: 1-9. doi: 10.1007/s00261-016-0875-8....
wild-type andmutant proteinforms. Because of its high specificity in distinguishing molecular mass,mass spectrometryhas been applied to detect the wild-type and mutantKRASproteins in pancreatic tumor tissue, cells, and cyst fluids[73–75]. Stable isotope-labeled synthetic reference peptides ...
KRAS status serves as a predictive biomarker of response to treatment in metastatic colorectal cancer (mCRC). We hypothesize that complex interactions between multiple pathways contribute to prognostic differences between KRAS wild-type and KRAS mutant patients with mCRC, and aim to identify polymorphism...
COL1A1: A potential therapeutic target for colorectal cancer expressing wild-Type or mutant KRAS 来自 Semantic Scholar 喜欢 0 阅读量: 123 作者:Z Zhang,F Cheng,Y Wang,J Zhang,Y Jian,Y Zhang,X Wang,J Zhong 摘要: Colorectal cancer (CRC) treatment primarily relies on chemotherapy along with ...
KRAS wild type and G12C-mutant cell lines [148]. The combination of ARS-853 and BAY-293 also showed synergistic antiproliferative activity in a KRAS G12C-mutant cell line. BI-3406, another tool compound targeting SOS1 was shown to have in vitro activity in KRAS G12X-mutant cell lines ...
LETTERS TO THE EDITOR study population twice, so these studies are arguably contributing more weight to the overall effect size than appropriate. Despite the concerns raised, we acknowledge that the meta-analysis presented by Cong et al (2014) has drawn attention to the potential role of ...